BiomX Inc. announced the completion of patient dosing in Part 2 of the Phase 1b/2a trial evaluating the Company?s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (CF). The Company remains on track to report results from Part 2 of the study in November 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.35 USD | +4.17% | +20.69% | +25.00% |
Apr. 18 | Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board | CI |
Apr. 03 | Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.00% | 19.33M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHGE Stock
- News BiomX Inc.
- BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis